E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 7.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012601 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To evaluate pulmonary lung function measured via serial spirometry after inhalation of Technosphere®/Insulin of non-asthmatic subjects with type 2 diabetes compared to asthmatic subjects with type 2 diabetes.
2. To evaluate the relative bioavailability and tolerability of plasma insulin following Technosphere®/Insulin administration in non-asthmatic subjects with type 2 diabetes compared to asthmatic subjects with type 2 diabetes.
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of inhaled Technosphere®/Insulin in asthmatic subjects with type 2 diabetes compared with non-asthmatic subjects with type 2 diabetes.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Eligible subjects must meet all of the following inclusion criteria:
Non-asthmatic Subjects: - Clinical diagnosis of type 2 diabetes mellitus. - Current basal and prandial insulin therapy for at least 6 weeks either as monotherapy or in combination with ≤ 2 oral anti-hyperglycemic agents. - HbA1c ≤ 12% at screening.
Asthmatic Subjects: - Clinical diagnosis of type 2 diabetes mellitus. - Clinical diagnosis and confirmation of asthma (NAEPP Step 1-3) for at least one year - Current basal and prandial insulin therapy for at least 6 weeks either as monotherapy or in combination with ≤ 2 oral anti-hyperglycemic agents. - FEV1/FVC ≤ Predicted Lower Limit of Normal - HbA1c ≤ 12% at screening.
|
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following will be excluded from the study:
- Diabetes mellitus type 1. - Total daily insulin requirement of ≥ 1.4U/kg. - Allergy to insulin or to any drugs to be used as part of the clinical trial, or history of hypersensitivity to the study drug or to drugs with similar chemical structures. - Clinical diagnosis and confirmation of Step 4 asthma. - Treatment with any investigational drug within 90 days prior to enrollment or during this study. - Previous history of anaphylaxis or angioedema. - Positive hepatitis B (HbsAg) HIV serology or active Hepatitis C (Hep C Ab) at screening. - Presence of pulmonary disease other than asthma (history of chronic obstructive pulmonary disease,chronic bronchitis, emphysema, occupational reactive airway disease).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for the spirometry testing portion of the study is change in FVC and FEV1 among the two subjects groups.
The primary parameters for the PK/PD part of the study are AUC PI (0-8 hours) and AUC GIR (0-8 hrs).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as the last patient last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |